Taconic Capital Advisors’s AbbVie ABBV Stock Holding History

Taconic Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-25,000	Closed	-$2.02M	–	47
2019 Q1	$2.02M	Buy	+25,000	New	+$2.05M	0.11%	45

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Taconic Capital Advisors's ABBV Position: Q2 2019 in Review

Taconic Capital Advisors sold out of AbbVie (ABBV) in Q2 2019, closing a stake of 25,000 shares — an estimated $2.02M sold.

Taconic Capital Advisors first reported a position in ABBV in Q1 2019 and held it in 1 quarter. The position peaked at $2.02M in Q1 2019. 2,021 funds tracked by Wall St. Rank hold ABBV as of Q2 2019.

Taconic Capital Advisors reported no remaining AbbVie position as of Q2 2019 after selling out during the quarter.
Taconic Capital Advisors sold 25,000 AbbVie shares in Q2 2019, an estimated $2.02M.
Taconic Capital Advisors first reported a position in AbbVie in Q1 2019 and held it in 1 quarter.
Taconic Capital Advisors's AbbVie position peaked at $2.02M in Q1 2019.
2,021 funds tracked by Wall St. Rank held AbbVie as of Q2 2019.

Based on Taconic Capital Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.